“The Middle Eastern and African markets represent key areas of unmet medical need and commercial opportunity for Caris Life Sciences, and demonstrate a significant leap forward for our international global expansion plans,” said Ian Walker, Vice President – International at Caris Life Sciences. “Partnering with IPS Genomix offers us a large, diverse and experienced team to help realize our goal to bring Caris Molecular Intelligence to patients and physicians across the globe.”

Caris Molecular Intelligence™ uses multiple evidence-guided profiling technologies — IHC, FISH/CISH, PCR and Next-Generation Sequencing – to provide oncologists with the most relevant, clinically actionable treatment information to help them personalise care for their patient. By identifying the biomarkers unique to a patient’s tumor, Caris can help the physician develop a treatment plan ranging from commercially available agents to active, openly enrolling clinical trials in the patient’s geography. Caris’ multi-technology approach assesses the molecular biology of a tumor in order to better understand the gene and protein alterations that may be driving its growth. Testing of multiple clinically relevant analytes in a tumor is typically most applicable for patients with aggressive, rare or refractory cancers where standard-of-care guidelines have been exhausted or are unclear, or where additional clinical trial options are desired.
Read more